Clinical Trials Logo
  1. Home
  2. Other
  3. NCT04984148

Construction of CT Radiomics Model for Predicting the Efficacy of Immunotherapy in Patients With Stage III NSCLC

Stage III Non-small Cell Lung Cancer Clinical Trial

Official title:
Construction of CT Radiomics Model to Assess PD-L1 Status and Predict the Efficacy of Chemoradiotherapy Combined With Immunotherapy in Unresectable Locally Advanced Non-small Cell Lung Cancer

Clinical Trial Summary

Consolidation immunotherapy of immune checkpoint inhibitor (ICI) following chemoradiotherapy (CRT) is the current standard of care for patients with unresectable locally advanced non-small cell lung cancer (NSCLC) as it improves both progression-free survival and overall survival. However, a substantial proportion of patients still experience disease recurrence despite consolidation ICI. It is important for personalized treatment to predict the efficacy of consolidation ICI. PD-L1 expression is used as a predictive biomarker for ICI response and efficacy in advanced NSCLC, but its role in patients with stage III disease is unclear. One important reason is PD-L1 testing performed on pre-CRT tissue may not reflect changes in PD-L1 expression after CRT. CT-based radiomics approaches have been successfully applied to generate imaging biomarkers as decision support tools for clinical practice. The hypothesis of this study is that CT radiomics model can assess PD-L1 status after CRT and predict the efficacy of CRT combined with ICI in unresectable locally advanced NSCLC.

Clinical Trial Description

This is an observational longitudinal prospective study. CT scan is performed before radiotherapy, during radiotherapy and at the end of radiotherapy in patients with unresectable locally advanced NSCLC who undergo CRT. Radiomic features were extracted from CT images and baseline PD-L1 expression is assessed. CT-based radiomics models is developed to assess PD-L1 expression and predict the efficacy of ICI. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04984148
Study type Observational
Source Guangdong Provincial People's Hospital
Contact Yi Pan
Phone +862083827812
Email panyiff011@163.com
Status Recruiting
Phase
Start date February 1, 2019
Completion date January 31, 2024
View Details
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05488626 - Daily Adaptive Radiation Therapy: An Individualized Approach for Stage III Lung Cancer N/A
Recruiting NCT02076282 - MRI Optimization Study in Stage III NSCLC N/A
Terminated NCT01577212 - Individualized Dose Prescription in Advanced Stage Lung Cancer Patients Using Modern (Chemo)Radiotherapy Phase 2
Withdrawn NCT01336543 - Consolidation Chemotherapy/Concurrent Chemo-radiotherapy for Inoperable Stage III Non-small Cell Lung Cancer (NSCLC) Phase 2
Completed NCT01102231 - Chemoradiotherapy in Stage III Non-small Cell Lung Cancer (NSCLC) Phase 2
Completed NCT00019006 - Vaccine Therapy in Treating Patients With Colon, Pancreatic, or Lung Cancer Phase 1
Recruiting NCT06082492 - The Beneficial Value of PET/CT in the Follow-up of Stage III Non-small Cell Lung Cancer Patients N/A
Active, not recruiting NCT03049618 - Recombinant EphB4-HSA Fusion Protein and Pembrolizumab, MK-3475 Phase 2
Recruiting NCT03077854 - Image-Guided Functional Lung Avoidance Thoracic Radiotherapy for Lung Cancer: A Single-Blind Randomized Trial N/A
Recruiting NCT05157542 - Neoadjuvant LDRT Combined With Durvalumab in Potentially Resectable Stage III NSCLC Phase 1
Recruiting NCT00938418 - Hypofractionated Intensity Modulated Chemoradiotherapy to Treat Locally Advanced Non-Small Cell Lung Cancer Phase 2
Recruiting NCT05361174 - A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer Phase 1/Phase 2
Active, not recruiting NCT03048500 - Nivolumab and Metformin Hydrochloride in Treating Patients With Stage III-IV Non-small Cell Lung Cancer That Cannot Be Removed by Surgery Phase 2
Not yet recruiting NCT05891080 - Neoadjuvant Therapy With Toripalimab and JS004 Combined With Platinum-based Doublet Chemotherapy for Resectable or Potentially Resectable Stage III Non-small Cell Lung Cancer: A Randomised Controlled, Open-label, Phase 2 Trial Phase 2
Active, not recruiting NCT01948141 - Nintedanib in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Failed Up to Two Previous Chemotherapy Regimens Phase 2
Completed NCT01282437 - Prophylactic Cranial Irradiation (PCI) vs Observation in Stage III NSCLC Phase 3
Recruiting NCT05631574 - Study of Covalent Menin Inhibitor BMF-219 in Adult Patients With KRAS Driven Non-Small Cell Lung Cancer, Pancreatic Cancer, and Colorectal Cancer Phase 1
Recruiting NCT05157503 - Treatment of Patients With Stage III Non-small Cell Lung Cancer in Russia"
Recruiting NCT05468242 - Study of Tislelizumab for Locally Advanced Non-Small Cell Lung Cancer Following Neoadjuvant Chemotherapy Plus Tislelizumab ± Bevacizumab and Definitive Concurrent Chemoradiation Therapy Phase 2
Active, not recruiting NCT06102057 - PACCELIO - FDG-PET Based Small Volume Accelerated Immuno Chemoradiotherapy in Locally Advanced NSCLC Phase 2